Next-Generation TIL(Obsidian Therapeutics)

N/A

Report date: 2024/09/04 09:19:56

Base Information

Drug NameNext-Generation TIL(Obsidian Therapeutics)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity

TargetsUpdating

Therapy Area/IndicationsN/A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesObsidian Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesObsidian Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsN/A

Inactive IndicationsN/A

Other Information

ATC CodeN/A